Lilly and Alcon to co-promote Arxxant
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Companies announce agreement July 21. Awaiting priority review at FDA, the diabetic retinopathy agent will be co-promoted to primary care physicians and endocrinologists. If approved, Arxxant (ruboxistaurin) would be a first-in-class treatment for the indication...